Amgen files update to Tavneos label as FDA escalates push to withdraw news2026-05-01T13:02:29+00:00May 1st, 2026|Endpoints News|
FDA’s oncology advisors vote against ‘new paradigm’ in AstraZeneca trialnews2026-04-30T18:56:01+00:00April 30th, 2026|Endpoints News|
House panel calls to ban China trial data from FDA drug trial applicationsnews2026-04-30T18:28:13+00:00April 30th, 2026|Endpoints News|
FDA, AstraZeneca prep for oncology adcommnews2026-04-29T18:32:20+00:00April 29th, 2026|Endpoints News|
FDA debuts plan to collect real-time clinical trial datanews2026-04-28T18:19:33+00:00April 28th, 2026|Endpoints News|
FDA claims trial ‘manipulation’ tainted approval of ChemoCentryx drugnews2026-04-28T13:09:24+00:00April 28th, 2026|Endpoints News|
Novartis pulls Pluvicto prostate cancer label expansion filing in the EUnews2026-04-24T14:49:37+00:00April 24th, 2026|Endpoints News|
FDA approves Regeneron’s hearing loss gene therapy Otarmeninews2026-04-23T18:53:40+00:00April 23rd, 2026|Endpoints News|
Post-Hoc Live: MAHA, the new Trump CDC pick and RFK’s vaccine agendanews2026-04-23T17:56:45+00:00April 23rd, 2026|Endpoints News|
Pharma-backed petition calls on FDA to reform release of drug rejection lettersnews2026-04-22T16:14:47+00:00April 22nd, 2026|Endpoints News|
